Dong-E-E-JiaoLtd Past Earnings Performance
Past criteria checks 5/6
Dong-E-E-JiaoLtd has been growing earnings at an average annual rate of 2.5%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been declining at an average rate of 5.5% per year. Dong-E-E-JiaoLtd's return on equity is 10.7%, and it has net margins of 24.4%.
Key information
2.5%
Earnings growth rate
2.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -5.5% |
| Return on equity | 10.7% |
| Net Margin | 24.4% |
| Next Earnings Update | 26 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Dong-E-E-JiaoLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4,715 | 1,151 | 1,839 | 173 |
| 30 Sep 23 | 4,424 | 1,051 | 1,781 | 130 |
| 30 Jun 23 | 4,383 | 1,003 | 1,733 | 130 |
| 31 Mar 23 | 4,220 | 896 | 1,727 | 131 |
| 01 Jan 23 | 4,042 | 780 | 1,668 | 138 |
| 30 Sep 22 | 4,070 | 652 | 1,563 | 157 |
| 30 Jun 22 | 3,988 | 599 | 1,538 | 153 |
| 31 Mar 22 | 4,006 | 493 | 1,534 | 147 |
| 01 Jan 22 | 3,849 | 440 | 1,414 | 148 |
| 30 Sep 21 | 4,195 | 366 | 1,783 | 129 |
| 30 Jun 21 | 4,001 | 277 | 1,600 | 140 |
| 31 Mar 21 | 3,705 | 189 | 1,500 | 148 |
| 31 Dec 20 | 3,409 | 43 | 1,399 | 154 |
| 30 Sep 20 | 2,181 | -685 | 1,450 | 147 |
| 30 Jun 20 | 2,175 | -732 | 1,541 | 164 |
| 31 Mar 20 | 2,116 | -932 | 1,617 | 178 |
| 31 Dec 19 | 2,970 | -455 | 1,765 | 205 |
| 30 Sep 19 | 5,784 | 1,069 | 2,018 | 285 |
| 30 Jun 19 | 6,243 | 1,416 | 2,105 | 277 |
| 31 Mar 19 | 6,934 | 1,869 | 2,176 | 270 |
| 31 Dec 18 | 7,338 | 2,085 | 2,198 | 241 |
| 30 Sep 18 | 7,276 | 2,023 | 2,183 | 233 |
| 30 Jun 18 | 7,424 | 2,005 | 2,082 | 303 |
| 31 Mar 18 | 7,392 | 2,049 | 2,081 | 259 |
| 31 Dec 17 | 7,372 | 2,044 | 2,178 | 226 |
| 30 Sep 17 | 6,813 | 1,873 | 2,165 | 116 |
| 30 Jun 17 | 6,577 | 1,925 | 2,145 | 0 |
| 31 Mar 17 | 6,510 | 1,913 | 2,143 | 0 |
| 31 Dec 16 | 6,317 | 1,852 | 2,096 | 0 |
| 30 Sep 16 | 5,649 | 1,721 | 1,792 | 0 |
| 30 Jun 16 | 5,577 | 1,682 | 1,776 | 0 |
| 31 Mar 16 | 5,501 | 1,643 | 1,726 | 0 |
| 31 Dec 15 | 5,450 | 1,625 | 1,681 | 0 |
| 30 Sep 15 | 5,190 | 1,572 | 1,600 | 0 |
| 30 Jun 15 | 4,830 | 1,516 | 1,432 | 0 |
| 31 Mar 15 | 4,494 | 1,464 | 1,315 | 0 |
| 31 Dec 14 | 4,009 | 1,366 | 1,110 | 0 |
| 30 Sep 14 | 3,769 | 1,265 | 1,011 | 0 |
| 30 Jun 14 | 3,990 | 1,282 | 1,148 | 0 |
| 31 Mar 14 | 3,995 | 1,247 | 1,135 | 0 |
| 31 Dec 13 | 4,016 | 1,203 | 1,152 | 0 |
| 30 Sep 13 | 4,047 | 1,162 | 1,370 | 0 |
| 30 Jun 13 | 3,660 | 1,116 | 1,238 | 0 |
Quality Earnings: 000423 has high quality earnings.
Growing Profit Margin: 000423's current net profit margins (24.4%) are higher than last year (19.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000423's earnings have grown by 2.5% per year over the past 5 years.
Accelerating Growth: 000423's earnings growth over the past year (47.8%) exceeds its 5-year average (2.5% per year).
Earnings vs Industry: 000423 earnings growth over the past year (47.8%) exceeded the Pharmaceuticals industry 8.2%.
Return on Equity
High ROE: 000423's Return on Equity (10.7%) is considered low.